NCT04328844 2026-03-30
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Phase 1 Active not recruiting
iOnctura
Inimmune Corporation
Universitair Ziekenhuis Brussel
EMD Serono
Merck KGaA, Darmstadt, Germany
Memorial Sloan Kettering Cancer Center
Jules Bordet Institute
Yonsei University
Vyriad, Inc.
Merck KGaA, Darmstadt, Germany